Office of Commercialization and Economic Development
Office of Technology Commercialization

Cell Line: UNCCF7T

Technology #19-0150

This is a growth enhanced cell line derived from primary epithelial cells originally obtained from the explanted lungs of a donor with cystic fibrosis, in accordance with an IRB-approved protocol, that underwent lung transplantation. The CFTR genotype is G542X homozygous, enabling this cell line to be used to study the biology and potential therapies for diseases created by premature termination codon mutations. The primary cells were growth enhanced by lentiviral delivery of two oncogenes, Bmi-1 and hTERT. Cells that are growth enhanced in this manner typically remain diploid and, when expanded and cultured appropriately, retain the ability to form resistive epithelial sheets suitable for testing on ion transport properties.